3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
6
Breast
4
Thoracic
3
Sarcoma
3
Other solid neoplasm
3
Lymphoid
2
Gastrointestinal
2
Tumor-Agnostic
1
Other hematologic neoplasm
1
NET
1
Head & Neck
1
Gynecologic
1
Endocrine
1
Conditions
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Sarcoma
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Gastro-enteropancreatic neuroendocrine tumor
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Interventions
lutetium Lu 177 dotatate
5
gallium Ga 68 dotatate
3
surufatinib
2
pembrolizumab
2
olaparib
2
lanreotide
2
atezolizumab
2
Everolimus
2
3-Iodobenzylguanidine
2
tivozanib
1
tislelizumab
1
repotrectinib
1
regorafenib
1
pralsetinib
1
irinotecan sucrosofate
1
cabozantinib
1
avelumab
1
arginyllysine
1
amino-acid, glucose, and electrolyte solution
1
Tirapazamine
1
Temozolomide
1
TKM-080301
1
S 1 (combination)
1
Radiotherapy
1
Positron-Emission Tomography
1
Positron Emission Tomography Computed Tomography
1
PT-100 dipeptide
1
PM 01183
1
Ondansetron
1
Magnetic Resonance Spectroscopy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Clinical Trials, Phase II as Topic
×
NET
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled